Number of the records: 1  

Histone deacetylase inhibitors for the treatment of cancer stem cells

  1. 1.
    SYSNO ASEP0469858
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleHistone deacetylase inhibitors for the treatment of cancer stem cells
    Author(s) Dvořáková, Marcela (UEB-Q) RID, ORCID
    Vaněk, Tomáš (UEB-Q) RID, ORCID
    Number of authors2
    Source TitleMedChemComm. - : Royal Society of Chemistry - ISSN 2040-2503
    Roč. 7, č. 12 (2016), s. 2217-2231
    Number of pages15 s.
    Languageeng - English
    CountryGB - United Kingdom
    Keywordsacute myeloid-leukemia ; epithelial-mesenchymal transition ; acute myelogenous leukemia ; tumor-initiating cells ; human aml cells ; breast-cancer ; hdac inhibitors ; sirtuin inhibitors ; colorectal-cancer ; anticancer agents
    Subject RIVCC - Organic Chemistry
    R&D ProjectsLD14128 GA MŠMT - Ministry of Education, Youth and Sports (MEYS)
    Institutional supportUEB-Q - RVO:61389030
    UT WOS000390552300002
    DOI10.1039/c6md00297h
    AnnotationTiny populations of tumor cells are present in solid and hematologic malignancies and are responsible for cancer development, metastasis and limited response to therapy; these are referred to as cancer stem cells (CSCs). CSCs are resistant to standard cancer treatments and are the main cause of tumor relapse. Therefore, the development of new therapeutics to overcome the resistance of CSCs is greatly required. It is known that epigenetic histone modifications (acetylation/deacetylation) play a crucial role in cancer development through regulation of gene expression. Deacetylation of histone and non-histone proteins controls cell proliferation, metabolism and apoptosis as well as DNA repair and differentiation. Thus, histone deacetylase inhibitors (HDACis) are a promising group of anti-cancer agents, showing the ability to induce growth arrest or apoptosis in tumor cells. In this review, we summarize the current knowledge about the prospects of HDACis utilization in the treatment of CSCs.
    WorkplaceInstitute of Experimental Botany
    ContactDavid Klier, knihovna@ueb.cas.cz, Tel.: 220 390 469
    Year of Publishing2017
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.